A Study to Investigate the Safety, Tolerability and Pharmacokinetics of OZ439 in Healthy Male and Female Subjects

NCT ID: NCT00928083

Last Updated: 2015-01-08

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE1
• Total Enrollment: 63 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2009-04-30
• Study Completion Date: 2009-12-31

Brief Summary

OZ439 is a synthetic trioxolane that has potential value as a peroxide antimalarial agent.

This was a Phase I, single-centre, multi-component, double-blind, randomised, placebo-controlled study in healthy male and female subjects. The study was conducted in 3 parts:

• Part A investigated the safety, tolerability and pharmacokinetics (PK) of single oral escalating doses of OZ439. Up to 6 dose levels will be investigated to estimate dose proportionality.
• Part B, the effect of food on a single oral dose of OZ439 was investigated in a 2-way crossover design.
• Part C investigated the safety, tolerability and PK profile of multiple oral doses of OZ439.

The starting oral dose was 50 mg and the maximum single dose to be administered did not exceed 1600 mg per subject. The maximum duration of dosing proposed was 3 days.

Conditions

Malaria Falciparum; Malaria Vivax; Healthy Volunteers

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: CROSSOVER
• Primary Study Purpose: TREATMENT
• Blinding Strategy: QUADRUPLE

Study Groups

Part A - 50 mg Single Dose

OZ439 Single doses of 50mg (capsules)

Group Type: EXPERIMENTAL

OZ439 50mg API capsules

Intervention Type: DRUG

Part A - 100mg Single Dose

OZ439 Single doses of 100mg (capsules)

Group Type: EXPERIMENTAL

OZ439 100mg API capsules

Intervention Type: DRUG

OZ439 100mg (2x50mg API capsules)

Part A - 200mg Single Dose

OZ439 Single doses of 200mg (capsules)

Group Type: EXPERIMENTAL

OZ439 200mg API capsules

Intervention Type: DRUG

Part A - 400mg Single Dose

OZ439 Single doses of 400mg (capsules)

Group Type: EXPERIMENTAL

OZ439 400mg API capsules

Intervention Type: DRUG

OZ439 400mg (2x200mg API capsules)

Part A - 400mg Single Dose + Food

OZ439 Single doses of 400mg (capsules) administered with food.

Group Type: EXPERIMENTAL

OZ439 400mg API capsules

Intervention Type: DRUG

OZ439 400mg (2x200mg API capsules)

Part A - 400mg AD Single Dose

OZ439 Single doses of 400mg (aqueous dispersion)

Group Type: EXPERIMENTAL

OZ439 400mg aqueous dispersion

Intervention Type: DRUG

Part A - 800mg Single Dose

OZ439 Single doses of 800mg (capsules)

Group Type: EXPERIMENTAL

OZ439 800mg API capsules

Intervention Type: DRUG

OZ439 800mg (4x200 API capsules)

Part A - 800mg AD Single Dose

OZ439 Single doses of 800mg (aqueous dispersion)

Group Type: EXPERIMENTAL

OZ439 800mg aqueous dispersion

Intervention Type: DRUG

Part A - 1200mg Single Dose

OZ439 Single doses of 1200mg (capsules)

Group Type: EXPERIMENTAL

OZ439 1200mg API capsules

Intervention Type: DRUG

OZ439 1200mg (6x200mg API capsules)

Part A - 1600mg AD Single Dose

OZ439 Single doses of 800mg (aqueous dispersion)

Group Type: EXPERIMENTAL

OZ439 1600mg aqueous dispersion

Intervention Type: DRUG

Part A - Placebo

Placebo control for Single rising Part A

Group Type: PLACEBO_COMPARATOR

Placebo

Intervention Type: DRUG

Part B - 800mg AD Single Dose Fed

Single dose of OZ439 800mg aqueous dispersion administered under fed conditions

Group Type: EXPERIMENTAL

OZ439 800mg aqueous dispersion

Intervention Type: DRUG

Part B - 800mg AD Single Dose Fast

Single dose of OZ439 800mg aqueous dispersion administered under fast conditions

Group Type: EXPERIMENTAL

OZ439 800mg aqueous dispersion

Intervention Type: DRUG

Part C - 200mg AD Multiple Dose

200mg aqueous solution OZ439 or placebo once daily for 3 days fasted

Group Type: EXPERIMENTAL

OZ439 200mg aqueous dispersion

Intervention Type: DRUG

Part C - 400mg AD Multiple Dose

400mg aqueous solution OZ439 or placebo once daily for 3 days fasted

Group Type: EXPERIMENTAL

OZ439 400mg aqueous dispersion

Intervention Type: DRUG

Part C - 800mg AD Multiple Dose

800mg aqueous solution OZ439 or placebo once daily for 3 days fasted

Group Type: EXPERIMENTAL

OZ439 800mg aqueous dispersion

Intervention Type: DRUG

Part C - Placebo

Placebo control for Multiple rising Part C

Group Type: PLACEBO_COMPARATOR

Placebo

Intervention Type: DRUG

Interventions

OZ439 50mg API capsules

Intervention Type: DRUG

OZ439 200mg API capsules

Intervention Type: DRUG

OZ439 400mg aqueous dispersion

Intervention Type: DRUG

OZ439 800mg aqueous dispersion

Intervention Type: DRUG

OZ439 100mg API capsules

OZ439 100mg (2x50mg API capsules)

Intervention Type: DRUG

OZ439 400mg API capsules

OZ439 400mg (2x200mg API capsules)

Intervention Type: DRUG

OZ439 1600mg aqueous dispersion

Intervention Type: DRUG

OZ439 800mg API capsules

OZ439 800mg (4x200 API capsules)

Intervention Type: DRUG

OZ439 1200mg API capsules

OZ439 1200mg (6x200mg API capsules)

Intervention Type: DRUG

Placebo

Intervention Type: DRUG

OZ439 200mg aqueous dispersion

Intervention Type: DRUG

Other Intervention Names

OZ439; OZ439; OZ439; OZ439; OZ439; OZ439; OZ439; OZ439; OZ439

Eligibility Criteria

Inclusion Criteria

1. Healthy male//female subjects between 18- 55 years of age (inclusive).

2. Body mass Index (BMI) between 18 - 30 kg/m2, inclusive; and a total body weight >60 kg (132 lbs).

3. Healthy as determined by pre-study medical history, PE, 12 Lead ECG.

4. Females of childbearing potential must use 1 of birth control methods throughout study and for 30 days after last dose of study drug:

1. Surgically sterile (bilateral tubal ligation, hysterectomy, bilateral oophorectomy) 6 months minimum prior to first dose of study drug.

2. Intrauterine device (IUD) in place for at least 3 months prior to first dose of study drug.

3. Barrier methods (condom or diaphragm) with spermicide starting at least 14 days prior to first dose of study drug through 30 days after last dose of study drug.

4. Surgical sterilization of the partner(s) (vasectomy with zero sperm count for 6 months minimum prior to the first dose of study drug).

5. Hormonal contraceptives starting at least 3 months prior to first dose of study drug. In addition, subjects must agree to use a barrier method (condom or diaphragm) with spermicide at least 14 days prior to first dose of study drug through 30 days after the last dose of study drug.

5. Post-menopausal women with amenorrhea for at least 1 year will be eligible confirmed by FSH.

6. Male subjects must agree to use double barrier method of contraception, from time of first dose of study drug through 90 days after last dose of study drug and must also agree to not donate sperm for 90 days after last dose of study drug. Clinical laboratory tests within the reference ranges.

7. Able/willing to give written informed consent.

8. Willing/to adhere to lifestyle guideline restrictions outlined in protocol.

9. Willing and able to be confined to Clinical Research Unit as required by the protocol.

Exclusion Criteria

1. Evidence/history of clinically significant oncologic, pulmonary, hepatic, cardiovascular, hematologic, metabolic, neurological, immunologic, nephrologic, endocrine, psychiatric disease, current infection.

2. Evidence/history of clinically significant gastrointestinal (some exclusions exist) disease, current infection.

3. Any condition that affecting drug absorption, e.g., gastrectomy.

4. History of post-antibiotic colitis.

5. Breast feeding.

6. QTc greater than 450 msec for males and 470 msec for females as corrected by the Bazett formula.

7. History of drug or alcohol abuse within the past 2 years prior to Screening.

8. Tobacco users

9. Received investigational drug/ participated in another research study within 30 days of first dose of study drug in any part of study.

10. Use of prescription drugs within 14 days prior to the first dose of study drug in Period 1, or need for any antibiotic during study.

11. Received any non prescription meds, vitamins, herbal/dietary supplements within 7 days of administration of first dose of study drug in Period 1 (exceptions exist)

12. Consumed alcohol within 72 hours of Day -1 in any part of study, or have a positive alcohol screen at screening or each admission to Clinical Research Unit (CRU).

13. Consumed grapefruit juice or juices containing grapefruit or ate grapefruit within 7 days prior to first dose of study drug in any part of study.

14. Positive serum pregnancy test at the Screening Visit or on Day -1 prior to inclusion in any part of the study.

15. Positive test for HIV-1, HBsAg,HCV.

16. Positive urine drug screen at Screening or admission to CRU.

17. History of intolerance/ hypersensitivity to artemisinins.

18. Likelihood of requiring treatment during study period with drugs not permitted by protocol.

19. Subjects who have donated blood or experienced significant blood loss within 60 days of screening for study.

20. Subjects whose hemoglobin is <12.5 g/dL for males/ <11.5 g/dL for females.

21. Any concern by investigator regarding safe participation of the subject in study or for any other reason investigator considers subject inappropriate for participation in study.

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 55 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: Yes

Sponsors

Medicines for Malaria Venture

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Joerg Moehrle, PhD

Role: STUDY_DIRECTOR

Medicines for Malaria Venture

Maria Gutierrez, MD

Role: PRINCIPAL_INVESTIGATOR

Comprehensive Phase One Miramar, 3400 Enterprise Way, Miramar, FL 33025

Locations

Comprehensive Phase One Miramar; 3400 Enterprise Way

Miramar, Florida, United States

Countries

United States

References

Moehrle JJ, Duparc S, Siethoff C, van Giersbergen PL, Craft JC, Arbe-Barnes S, Charman SA, Gutierrez M, Wittlin S, Vennerstrom JL. First-in-man safety and pharmacokinetics of synthetic ozonide OZ439 demonstrates an improved exposure profile relative to other peroxide antimalarials. Br J Clin Pharmacol. 2013 Feb;75(2):524-37. doi: 10.1111/j.1365-2125.2012.04368.x.

Reference Type: RESULT

PMID: 22759078 (View on PubMed)

Other Identifiers

MMV_OZ439_09_001

Identifier Type: -

Identifier Source: org_study_id